Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly true Scientifically well supported Certainty of evidence: high provisional C-INS-04

Large trials in type 2 diabetes showed that intensive glucose lowering towards normal HbA1c can be harmful: ACCORD was stopped after intensive therapy raised all-cause mortality by 22%, and severe hypoglycaemia was associated with roughly doubled mortality.

In short: This claim is mostly true. ACCORD found 22% higher mortality with very intensive glucose lowering in high-risk type 2 diabetes, and the cardiovascular-death excess persisted at 9 years, but total mortality became neutral, hypoglycaemia did not explain the excess, and moderate control remains beneficial.
Conclusion: Correct: aggressive near-normal targets can harm high-risk type 2 patients; this supports moderate, individual targets, not abandoning treatment.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

التجارب الكبرى مثل ACCORD أوقفت العلاج المكثف مبكرًا بعد أن رفع الوفيات 22%، وأظهر تحليل Bonds أن نقص السكر الحاد المصحوب بأعراض ضاعف الوفيات في ذراعَي الدراسة.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Large trials in type 2 diabetes showed that intensive glucose lowering towards normal HbA1c can be harmful: ACCORD was stopped after intensive therapy raised all-cause mortality by 22%, and severe hypoglycaemia was associated with roughly doubled mortality.

Origin

Source status
Archive editors
Attribution
Archive editors (not Elawady)
Origin
https://eltayebat.com/rule/insulin-injections/
Attribution uncertainty
Editorial narrative and study selection written by the archive operators.
Claimed mechanism

Over-intensification causes hypoglycaemia and other harms.

Claimed health effect

Higher mortality, severe hypoglycaemia, weight gain

Population concerned

High-risk, long-standing type 2 diabetes

Geographic restriction by Elawady

none found

Diverging source versions

Source status
Archive editors
Attribution
Archive editors (not Elawady)
Origin
https://eltayebat.com/rule/oral-diabetes-drugs/
Attribution uncertainty
Editorial narrative and study selection written by the archive operators.

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: high – Further research is very unlikely to change the assessment.

1. What was claimed?

Intensive glucose lowering in type 2 diabetes increased mortality (ACCORD) and severe hypoglycaemia is linked to death.

2. What is demonstrably correct?

ACCORD: 10,251 patients, target HbA1c <6.0%: 257 vs 203 deaths, HR 1.22 (95% CI 1.01-1.46); the intensive arm was stopped after 3.5 years; no significant reduction of the primary cardiovascular outcome (HR 0.90) (A-INS-01). Full text reports death from cardiovascular causes HR 1.35 (1.04-1.76), so the archive's 35% figure is correct. VADT found no benefit on major cardiovascular events or death (HR 1.07) and more adverse events, mainly hypoglycaemia (A-INS-03). Severe hypoglycaemia was associated with higher mortality in ACCORD (adjusted HR 1.41 intensive, 2.30 standard arm) (A-INS-14) and with macrovascular events (HR 2.88) and death (HR 2.69) in ADVANCE (A-INS-15). In critically ill patients, tight glucose control (4.5-6.0 mmol/L) increased 90-day mortality (A-INS-02). ADA 2026 states that clinicians 'should not aggressively attempt to achieve near-normal A1C levels' where this cannot be done safely (I-INS-10).

3. What is wrong or exaggerated?

The archive's Arabic headline attributes the ACCORD harm to 'high insulin doses'; ACCORD tested a treatment strategy using many drugs (in the intensive arm 94.7% metformin, 91.7% thiazolidinedione, 86.6% secretagogue and 77.3% any insulin, per full text) and could not attribute the excess mortality to any single drug. Bonds et al. explicitly concluded that hypoglycaemia did not appear to account for the mortality difference between arms (A-INS-14). ADVANCE (target HbA1c <=6.5%) found a 10% reduction in combined major macro- and microvascular events, mainly nephropathy, and no increase in death (HR 0.93) (I-INS-01). UKPDS showed microvascular benefit (A-INS-16) and long-term reductions of myocardial infarction and death (I-INS-02); in type 1 diabetes intensive insulin therapy reduced retinopathy by 76% (I-INS-03). The archive's statement that severe hypoglycaemia doubled mortality 'in both arms' is correct only for the standard arm (adjusted HR 2.30); in the intensive arm the adjusted HR was 1.41 (A-INS-14).

4. What remains unclear?

The exact mechanism of excess death in ACCORD remains unexplained. In 9-year follow-up (ACCORDION) the excess of cardiovascular death persisted but was smaller (HR 1.20, 1.03-1.39), while all-cause mortality became neutral (I-INS-123).

5. Which studies support it?

A-INS-01, A-INS-02, A-INS-03, A-INS-14, A-INS-15, I-INS-10.

6. Which studies contradict it?

I-INS-01, I-INS-02, I-INS-03, A-INS-16 (benefits of good, non-extreme control).

7. What applies to Germany and Europe?

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

8. What is known about Egypt?

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. What practical conclusion is appropriate?

This part of the archive is accurate and matches current guidelines: HbA1c targets should be individualised (often <7%), less strict for frail or older people, and treatment should avoid hypoglycaemia. It does not support the conclusion that lowering high blood glucose is harmful in general.

Assessment details

Rationale for certainty of evidence

Directly reported RCT results (ACCORD abstract; cardiovascular death HR 1.35 confirmed in full text). Consistent with VADT, ADVANCE and current guidelines. Downgraded from “True” because the archive omits that ADVANCE showed microvascular benefit, that hypoglycaemia did not explain the ACCORD mortality excess, and that the harm concerned a near-normal target in high-risk patients, not glucose lowering in general.

Source quality

Archive editorial correctly quoting RCTs.

Regional transferability

Trials were multinational (US/Canada, ADVANCE incl. Europe/Asia); transferable.

Individual exceptions

Younger people early in the disease without cardiovascular disease may benefit from lower targets if achieved safely (ADA 2026, I-INS-10).

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Scientifically well supported – The claim agrees with consistent, high-quality evidence.

Research question: In type 2 diabetes, does intensive glucose lowering towards normal HbA1c increase mortality, and is severe hypoglycaemia associated with higher mortality?

Research question in detail (PICO)
Population
High-risk adults with long-standing type 2 diabetes
Intervention or exposure
Intensive glycaemic control (HbA1c <6.0-6.5%)
Comparison
Standard control
Geographic scope
universal biology
Outcomes
  • All-cause and CV mortality
  • Severe hypoglycaemia

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Near-normal HbA1c targets pursued aggressively in high-risk long-standing T2D can increase CV mortality; moderate, individualised control is beneficial.

Why some studies weigh more

Multiple large RCTs and long-term follow-ups.

Is a causal relationship established? Yes, established Randomised evidence.

Remaining uncertainty

Mechanism of ACCORD excess deaths.

Justified conclusion

Mostly true as reported by the archive.

Why do studies seem to disagree?

ACCORD vs ADVANCE/UKPDS differ in population (high-risk long-standing vs newly diagnosed), speed of intensification and targets.

Does this depend on the country?
General biological effects
Trials were multinational; findings apply to similar high-risk populations.
Eating habits
Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
Origin of the food
Not relevant.
Contaminants
Not relevant.
National production conditions
Not relevant.
Legal rules
Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
Actual monitoring data
Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Absolute risk difference, NNH, CI symmetry – Mortality 5.01% vs 3.96%; ARD 1.05 points (0.25-1.85); NNH about 95 over 3.5 years; HR CI log-symmetric recalculated
  • CI symmetry – HR 1.20 (1.03-1.39) symmetric recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
All-cause mortality with near-normal HbA1c targets in high-risk T2D
Starting level
high (randomised trials)
Reasons for downgrading
  • inconsistency (ADVANCE, VADT neutral)
Result
moderate

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · Original publication
    People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD).
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
PubMed26 October 2026"Nine-Year Effects of 3.7 Years of Intensive Glycemic Control"both directions1
Europe PMC26 October 2026(TITLE:"intensive glucose") AND (TITLE:"meta-analysis") AND (mortality OR "cardiovascular")both directions16
PubMed26 October 2026Hemmingsen B[au] AND intensive glycaemic control AND Cochrane Database Syst Rev[ta]both directions3
PubMed26 October 2026ACCORD AND "9-year" AND mortality AND Diabetes Care[ta]both directions2

Open questions

The Cochrane review on intensive vs conventional control in T2D (Hemmingsen 2013, PMID 24214280) was withdrawn in 2015 (PMID 26222248) and was not used.

How deeply was this checked?

13 linked studies: 6 checked in full text (3 of them with a structured risk-of-bias assessment), 7 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly true (high)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (high)
    ACCORDION confirms a persistent CV-death excess while total mortality became neutral; this refines but does not change the verdict. Certainty for the claim as a whole (multiple RCTs reporting these figures) remains high even though the mortality outcome alone is inconsistent across trials.
    New sources: I-INS-123

In plain language

Very large studies tested whether pushing blood sugar down to almost normal levels helps people with long-standing type 2 diabetes and heart risk. In one study (ACCORD), more people died with the very aggressive approach, and very low blood sugar episodes were linked to death. Other studies showed that good but not extreme control protects the kidneys, eyes and nerves. Doctors therefore now set personal targets and try to avoid low blood sugar.

Studies on this claim

Studies supporting the claim (8)

  • Very aggressive blood sugar lowering in high-risk type 2 diabetes

    Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
    Randomised controlled trialcited by the Tayebat archivefull text checked★ key study

    Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?

    How was the study done?

    Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy

    How many people, animals or samples were studied?

    10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors

    What was actually found?

    More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.

    How large was the observed effect?

    HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome

    What do the results mean in everyday life?

    Very strict sugar targets are not good for everyone, especially older people with heart disease.

    What are the study's limitations?

    Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes

    What does it say about Elawady's specific claim?

    Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).

    Do the results apply to Germany and Europe?

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    What can explicitly not be concluded from this study?

    That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.

    Scientific details →

  • Very tight blood sugar control in intensive care

    NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
    Randomised controlled trialcited by the Tayebat archiveabstract checked

    Aiming for normal blood sugar in ICU patients raised deaths from 24.9% to 27.5%.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Optimal blood glucose target in critically ill ICU patients

    How was the study done?

    International multicentre RCT

    How many people, animals or samples were studied?

    6,104; Adult ICU patients expected to stay >=3 days

    What was actually found?

    Higher 90-day mortality and 13-fold more severe hypoglycaemia with intensive control.

    How large was the observed effect?

    OR 1.14 (1.02-1.28)

    What do the results mean in everyday life?

    In very sick hospital patients, moderate sugar targets are safer.

    What are the study's limitations?

    ICU population, not ambulatory diabetes; Open-label

    What does it say about Elawady's specific claim?

    Supports that overly tight targets harm (C-INS-04); both arms received insulin, so it does not support insulin avoidance.

    Do the results apply to Germany and Europe?

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    What can explicitly not be concluded from this study?

    Anything about insulin therapy in people with diabetes at home.

    Scientific details →

  • Intensive sugar control in veterans with long diabetes

    Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
    Randomised controlled trialcited by the Tayebat archiveabstract checked

    Lower sugar did not reduce heart events or deaths, and side effects (mainly hypoglycaemia) were more frequent.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Effect of intensive glucose control on CV events in long-standing type 2 diabetes

    How was the study done?

    Multicentre RCT

    How many people, animals or samples were studied?

    1,791; Military veterans, mean age 60.4, diabetes 11.5 years, 40% prior CV event

    What was actually found?

    No significant reduction in CV events or death; more adverse events.

    How large was the observed effect?

    HR 0.88 (0.74-1.05) primary; HR 1.07 death

    What do the results mean in everyday life?

    In long-standing diabetes, very intensive control brings little benefit and more low-sugar episodes.

    What are the study's limitations?

    Smaller sample, limited power; Mostly men

    What does it say about Elawady's specific claim?

    Supports C-INS-04 (no CV benefit, more hypoglycaemia).

    Do the results apply to Germany and Europe?

    US veterans; transferable with caution (mostly men).

    What can explicitly not be concluded from this study?

    That moderate glucose control is useless or that insulin causes death.

    Scientific details →

  • Severe low blood sugar and death in ACCORD

    Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
    Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key study

    People who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Link between severe hypoglycaemia and mortality in ACCORD

    How was the study done?

    Retrospective epidemiological analysis within an RCT (ACCORD)

    How many people, animals or samples were studied?

    10,194; ACCORD participants with hypoglycaemia assessment

    What was actually found?

    Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.

    How large was the observed effect?

    aHR 1.41 (1.03-1.93) intensive arm

    What do the results mean in everyday life?

    Severe hypoglycaemia is a danger sign to avoid.

    What are the study's limitations?

    Post-hoc observational analysis; Confounding by frailty

    What does it say about Elawady's specific claim?

    Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.

    Do the results apply to Germany and Europe?

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    What can explicitly not be concluded from this study?

    That hypoglycaemia caused the ACCORD excess mortality.

    Scientific details →

  • Severe hypoglycaemia in ADVANCE

    Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
    Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment

    Severe low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Severe hypoglycaemia and vascular events/death

    How was the study done?

    Post-hoc cohort analysis of an RCT (ADVANCE)

    How many people, animals or samples were studied?

    11,140; ADVANCE participants with type 2 diabetes

    What was actually found?

    aHR 2.69 death.

    How large was the observed effect?

    aHR 2.69 (1.97-3.67)

    What do the results mean in everyday life?

    Avoid severe hypoglycaemia.

    What are the study's limitations?

    Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.

    What does it say about Elawady's specific claim?

    Supports C-INS-04; kernel of C-INS-02.

    Do the results apply to Germany and Europe?

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    What can explicitly not be concluded from this study?

    Causation.

    Scientific details →

  • Very aggressive blood sugar lowering in high-risk type 2 diabetes

    Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
    Randomised controlled trialcited by the Tayebat archivefull text checked★ key study

    Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?

    How was the study done?

    Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy

    How many people, animals or samples were studied?

    10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors

    What was actually found?

    More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.

    How large was the observed effect?

    HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome

    What do the results mean in everyday life?

    Very strict sugar targets are not good for everyone, especially older people with heart disease.

    What are the study's limitations?

    Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes

    What does it say about Elawady's specific claim?

    Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).

    Do the results apply to Germany and Europe?

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    What can explicitly not be concluded from this study?

    That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.

    Scientific details →

  • Intensive sugar control in veterans with long diabetes

    Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
    Randomised controlled trialcited by the Tayebat archiveabstract checked

    Lower sugar did not reduce heart events or deaths, and side effects (mainly hypoglycaemia) were more frequent.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Effect of intensive glucose control on CV events in long-standing type 2 diabetes

    How was the study done?

    Multicentre RCT

    How many people, animals or samples were studied?

    1,791; Military veterans, mean age 60.4, diabetes 11.5 years, 40% prior CV event

    What was actually found?

    No significant reduction in CV events or death; more adverse events.

    How large was the observed effect?

    HR 0.88 (0.74-1.05) primary; HR 1.07 death

    What do the results mean in everyday life?

    In long-standing diabetes, very intensive control brings little benefit and more low-sugar episodes.

    What are the study's limitations?

    Smaller sample, limited power; Mostly men

    What does it say about Elawady's specific claim?

    Supports C-INS-04 (no CV benefit, more hypoglycaemia).

    Do the results apply to Germany and Europe?

    US veterans; transferable with caution (mostly men).

    What can explicitly not be concluded from this study?

    That moderate glucose control is useless or that insulin causes death.

    Scientific details →

  • ADA guideline 2026: blood sugar goals and emergencies

    American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
    Guideline / position statementindependent cross-checkfull text checked★ key study

    Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Glycaemic goals, hypoglycaemia and hyperglycaemic crises

    How was the study done?

    Clinical practice guideline (ADA Standards of Care 2026, Section 6)

    How many people, animals or samples were studied?

    not applicable; People with diabetes

    What was actually found?

    Individual targets; do not stop basal insulin when not eating.

    How large was the observed effect?

    not applicable

    What do the results mean in everyday life?

    Moderate targets and safety rules.

    What are the study's limitations?

    US-centred; Partially read

    What does it say about Elawady's specific claim?

    Supports C-INS-04, C-INS-11; contradicts C-FAST-01, C-FAST-03, C-DIAB-02.

    Do the results apply to Germany and Europe?

    Consistent with EASD guidance.

    What can explicitly not be concluded from this study?

    Not applicable.

    Scientific details →

Studies contradicting or limiting the claim (3)

  • ADVANCE: intensive control to HbA1c 6.5%

    ADVANCE Collaborative Group; Patel A et al.. N Engl J Med 2008 · PMID 18539916 · DOI 10.1056/NEJMoa0802987
    Randomised controlled trialindependent cross-checkfull text, structured risk-of-bias assessment★ key study

    Fewer kidney complications and no extra deaths, but more severe hypoglycaemia.

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Effect of intensive glucose control (gliclazide MR-based, HbA1c <=6.5%) on vascular outcomes

    How was the study done?

    Multicentre factorial RCT (ADVANCE glucose arm)

    How many people, animals or samples were studied?

    11,140; Type 2 diabetes with high vascular risk

    What was actually found?

    10% fewer combined events; no mortality difference.

    How large was the observed effect?

    HR 0.90 (0.82-0.98)

    What do the results mean in everyday life?

    Moderately intensive control is safe and protects kidneys.

    What are the study's limitations?

    Open-label; kidney benefit mainly less protein in urine; underpowered for heart attacks/strokes; funded by the drug's manufacturer (analysis independent).

    What does it say about Elawady's specific claim?

    Limits C-INS-04 (intensive control is not uniformly harmful); contradicts C-ODD-11.

    Do the results apply to Germany and Europe?

    Multinational trial including European sites or directly applicable to EU practice.

    What can explicitly not be concluded from this study?

    Benefit for heart attacks/stroke.

    Scientific details →

  • UKPDS legacy: 10 years after the trial

    Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    People treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Do UKPDS benefits persist and do macrovascular effects emerge?

    How was the study done?

    Post-trial monitoring of an RCT (UKPDS 80)

    How many people, animals or samples were studied?

    4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS

    What was actually found?

    Legacy reductions in MI and death.

    How large was the observed effect?

    Death -13% (SU/insulin), -27% (metformin)

    What do the results mean in everyday life?

    Early good control pays off for decades.

    What are the study's limitations?

    Post-trial therapy not controlled; Questionnaire follow-up

    What does it say about Elawady's specific claim?

    Contradicts C-INS-03, C-INS-05 and C-DIAB-01: early insulin/SU therapy reduced MI and death long-term.

    Do the results apply to Germany and Europe?

    UK; directly relevant.

    What can explicitly not be concluded from this study?

    Effects of extreme targets in late disease.

    Scientific details →

  • DCCT: better insulin treatment in type 1 diabetes

    Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    Intensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Does intensive insulin therapy reduce long-term complications in type 1 diabetes?

    How was the study done?

    Multicentre RCT (DCCT)

    How many people, animals or samples were studied?

    1,441; Insulin-dependent (type 1) diabetes

    What was actually found?

    Large reductions in all microvascular complications.

    How large was the observed effect?

    Retinopathy -76%

    What do the results mean in everyday life?

    Insulin protects eyes, kidneys and nerves in type 1 diabetes.

    What are the study's limitations?

    Open-label; Selected young population

    What does it say about Elawady's specific claim?

    Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).

    Do the results apply to Germany and Europe?

    North American; universally accepted.

    What can explicitly not be concluded from this study?

    Effects in type 2 diabetes directly.

    Scientific details →

Studies with mixed or unclear results (2)

  • UKPDS: tablets or insulin for new type 2 diabetes

    UKPDS Group. Lancet 1998 · PMID 9742976
    Randomised controlled trialcited by the Tayebat archiveabstract checked★ key study

    Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Intensive control with sulfonylurea or insulin vs diet on complications

    How was the study done?

    Multicentre RCT (UKPDS 33)

    How many people, animals or samples were studied?

    3,867; Newly diagnosed type 2 diabetes, median age 54

    What was actually found?

    Microvascular -25%; more hypoglycaemia and weight gain with insulin.

    How large was the observed effect?

    RR reduction 25% microvascular

    What do the results mean in everyday life?

    Insulin helps prevent complications but has side effects.

    What are the study's limitations?

    Open-label; Older drug regimens

    What does it say about Elawady's specific claim?

    Supports weight/hypoglycaemia (C-INS-01); contradicts C-INS-03, C-INS-05, C-DIAB-01.

    Do the results apply to Germany and Europe?

    UK; directly relevant.

    What can explicitly not be concluded from this study?

    That insulin is harmful overall.

    Scientific details →

  • ACCORD nine years later

    ACCORD Study Group. Diabetes Care 2016 · PMID 26822326 · DOI 10.2337/dc15-2283
    Randomised controlled trialindependent cross-checkabstract checked★ key study

    Very intensive sugar lowering in high-risk type 2 diabetes still showed more cardiovascular deaths after 9 years, but overall deaths were no longer different.

    CV death remained raised (HR 1.20), but all-cause death neutral at 9 years.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Follow ACCORD participants long term.

    How was the study done?

    Post-trial follow-up.

    How many people, animals or samples were studied?

    8,601 people.

    What was actually found?

    CV death HR 1.20; all-cause death neutral.

    How large was the observed effect?

    HR 1.20 (1.03-1.39).

    What do the results mean in everyday life?

    Very aggressive targets are not advisable for high-risk patients.

    What are the study's limitations?

    Post-trial care varied.

    What does it say about Elawady's specific claim?

    Supports caution; adds that total mortality became neutral.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Cannot attribute harm to insulin alone.

    Scientific details →

Regional context

Germany / EU

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

Egypt

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

What applies in my country?

General scientific assessment

Mostly true Correct: aggressive near-normal targets can harm high-risk type 2 patients; this supports moderate, individual targets, not abandoning treatment.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
  2. Intensive versus conventional glucose control in critically ill patients.. NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
  3. Glucose control and vascular complications in veterans with type 2 diabetes.. Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
  4. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
  5. Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
  6. Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
  7. Glucose control and vascular complications in veterans with type 2 diabetes.. Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
  8. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
  9. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.. ADVANCE Collaborative Group; Patel A et al.. N Engl J Med 2008 · PMID 18539916 · DOI 10.1056/NEJMoa0802987
  10. 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
  11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
  12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
  13. Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.. ACCORD Study Group. Diabetes Care 2016 · PMID 26822326 · DOI 10.2337/dc15-2283

← Back to overview